Non Alcoholic Fatty Liver Disease Market Summary

Non-Alcoholic Fatty Liver Disease Market & Epidemiology Analysis

• Non-Alcoholic Fatty Liver Disease (NAFLD), now called metabolic dysfunction-associated steatotic liver disease (MASLD), is an umbrella term that encompasses the entire spectrum of fatty liver disease, from simple steatosis to more progressive steatosis with associated hepatitis, fibrosis, cirrhosis, and in some cases hepatocellular carcinoma.
• Nonalcoholic fatty liver disease often has no symptoms, but when they do occur, they typically include fatigue, weakness, and abdominal discomfort or pain. As MASLD progresses to NASH (MASH), additional symptoms may appear, such as jaundice, severe itching, ascites, edema, and sometimes mental confusion.
• It is more common in male as compared to female.
• Currently, there is no FDA approved treatment specifically for nonalcoholic fatty liver disease (both NAFL and NASH). The only treatment available is for NASH and which has been recently approved.
• In March 2024, the US FDA granted accelerated approval for REZDIFFRA in conjunction with diet and exercise for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). Continued approval for this indication may be contingent upon verification and description of clinical benefit in ongoing confirmatory trials.
• However, prior to REZDIFFRA’s approval, several companies discontinued development within MASH due to competitive pressures and failure to demonstrate efficacy in clinical trials, resulting in the waning interest from biopharmaceutical companies.
• Major Non-Alcoholic Fatty Liver Disease Companies are getting involved in enhancing the treatment landscape.
• For instance, Novo Nordisk entered a USD 500 million co-development partnership deal with US-based Cellarity for the discovery and development of a small molecule drug for MASH using Cellarity’s artificial intelligence (AI) platform. This follows Novo Nordisk’s co-development partnership with Gilead Sciences, forged in March 2021, to conduct a Phase II trial of its GLP1R agonist OZEMPIC (semaglutide).

Request for Unlocking the Sample Page of the "NAFLD Treatment Market"

Key Factors Driving the Non-Alcoholic Fatty Liver Disease Market Growth

• Rising Global Prevalence of Obesity and Metabolic Syndrome

Increasing rates of obesity, insulin resistance, diabetes, and metabolic disorders are major contributors to the expanding NAFLD patient pool.

• Growing Awareness and Improved Diagnosis

Enhanced screening programs, wider clinical recognition, and advancements in non-invasive diagnostic tools are helping identify more NAFLD cases.

• Shift Toward Non-Invasive Biomarkers and Imaging

Adoption of technologies like FibroScan, MRI-based assessments, and blood-based biomarkers is improving disease detection and monitoring.

• Increasing Research and Development Activities

Multiple pharmaceutical companies are investing heavily in developing targeted therapies and novel mechanisms of action for NAFLD and NASH.

• Strong Pipeline of Emerging Therapies

A robust clinical pipeline, including metabolic modulators, anti-fibrotic agents, and combination therapies, is expected to drive future market expansion.

• Rise in Lifestyle-Related Risk Factors

Sedentary behavior, unhealthy diets, and increasing alcohol-free liver diseases are contributing to higher disease incidence globally.

DelveInsight's “Non-Alcoholic Fatty Liver Disease Treatment Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Non-Alcoholic Fatty Liver Disease, historical and forecasted epidemiology as well as the Non-Alcoholic Fatty Liver Disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Non-Alcoholic Fatty Liver Disease Treatment Market Report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM Non-Alcoholic Fatty Liver Disease market size from 2020 to 2034. The report also covers current Non-Alcoholic Fatty Liver Disease treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Non-Alcoholic Fatty Liver Disease Understanding and Treatment Algorithm

Non-Alcoholic Fatty Liver Disease Overview, Country-Specific Treatment Guidelines and Diagnosis

Nonalcoholic fatty liver disease (NAFLD), now called metabolic dysfunction-associated steatotic liver disease (MASLD), is the buildup of extra fat in liver cells that is not caused by alcohol. It is normal for the liver to contain some fat. However, if more than 5% – 10% percent of the liver’s weight is fat, then it is called a fatty liver (steatosis). The more advanced form of NAFLD is nonalcoholic steatohepatitis (NASH), now called metabolic dysfunction-associated steatohepatitis (MASH). NASH causes the liver to swell and become damaged. Nonalcoholic fatty liver disease tends to develop in people who are overweight or obese or have diabetes, high cholesterol, or high triglycerides. These conditions combined are known as metabolic syndrome. Rapid weight loss and poor eating habits also may lead to NAFLD. Certain medications may increase one’s chances of developing NAFLD.

The Non-Alcoholic Fatty Liver Disease report provides an overview of Non-Alcoholic Fatty Liver Disease pathophysiology, diagnostic approaches, and detailed treatment algorithm along with a real-world scenario of a patient’s journey beginning from the first symptom, the time taken for diagnosis to the entire treatment process.

Further details related to country-based variations in diagnosis are provided in the report

Non-Alcoholic Fatty Liver Disease Treatment

There are no medications approved yet for nonalcoholic fatty liver disease (now called MASLD). Eating a healthy diet and adding physical movement to the day may help prevent liver damage from starting or reverse it in the initial stages. It is generally recommended to lose at least 10% of the body weight, though even a 3% to 5% reduction can be beneficial. In some cases, weight-loss surgery or medications may be helpful. For individuals with NASH and moderate to severe liver scarring, a new medication called REZDIFFRA (resmetirom) is available. This drug helps reduce fat accumulation in the liver but is not recommended for those with cirrhosis. In cases where NASH has progressed to cirrhosis, a liver transplant may be necessary. 

Non-Alcoholic Fatty Liver Disease Epidemiology

The Non-Alcoholic Fatty Liver Disease epidemiology chapter in the report provides historical as well as forecasted in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2024 to 2034. The Non-Alcoholic Fatty Liver Disease epidemiology is segmented with detailed insights into Total NAFLD Prevalent Cases, Gender-specific Prevalent Cases, Age-specific Prevalent Cases, Stage-specific Prevalent Cases, Diagnosed and Treatable Cases of Non-Alcoholic Fatty Liver Disease.

Key findings from the NAFLD Epidemiological Analysis

• Nonalcoholic fatty liver disease is a leading cause of chronic liver disease globally.
• As per the American Liver Foundation (2024), about 100 million people (about 25%) in the US are estimated to have nonalcoholic fatty liver disease (now called MASLD).
• According to the findings, nonalcoholic fatty liver disease (now called MASLD) prevalence is higher in males in comparison to females.

Non-Alcoholic Fatty Liver Disease Market Recent Breakthroughs and Developments

• In November 2025, Novo Nordisk A/S initiated a study to evaluate whether a combination of two medicines—NNC0194-0499 and semaglutide—can reduce liver damage in patients with nonalcoholic steatohepatitis (NASH). NNC0194-0499 is an investigational therapy that targets liver function, while semaglutide is a well-established medication widely used for treating type 2 diabetes in many countries. Semaglutide also supports weight loss and may help reduce liver damage, potentially preventing future liver-related complications.
• In November 2025, Boehringer Ingelheim announced a study designed to determine whether survodutide can help individuals who are overweight or living with obesity—and who have confirmed or suspected NASH—by reducing liver fat and supporting weight loss. Participants are randomly assigned to two groups: one group receives different doses of survodutide, while the other receives a placebo. The placebo resembles survodutide but does not contain any active medication.

Non-Alcoholic Fatty Liver Disease Drugs Analysis

The drug chapter segment of the Non-Alcoholic Fatty Liver Disease Therapeutics Market Report encloses a detailed analysis of Non-Alcoholic Fatty Liver Disease Marketed Drugs and late-stage (Phase III and Phase II) Non-Alcoholic Fatty Liver Disease Pipeline Drugs. It also deep dives into the Non-Alcoholic Fatty Liver Disease pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations. 

Non-Alcoholic Fatty Liver Disease Marketed Drugs

• REZDIFFRA (resmetirom): Madrigal Pharmaceutical

Rezdiffra is a once-daily, oral THR-β agonist designed to target key underlying causes of nonalcoholic steatohepatitis. The accelerated approval of REZDIFFRA was based on results from the Phase III MAESTRO-NASH trial.It is with diet and exercise to treat adults with nonalcoholic steatohepatitis with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.

Non-Alcoholic Fatty Liver Disease Emerging Drugs

• Semaglutide: Novo Nordisk

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown promise in the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH). It has been approved for reducing the risk of heart attack and stroke in adults with cardiovascular disease and obesity. Currently, it is in Phase III of its clinical development for the treatment of MASH.

• Lanifibranor: Inventiva Pharma

Lanifibranor is an oral small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (“PPAR”) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of MASH/NASH. Currently, it is in Phase III of its clinical development.

Non-Alcoholic Fatty Liver Disease Market Outlook

The Non-Alcoholic Fatty Liver Disease Market Outlook is poised for significant growth, driven by the rising prevalence of obesity, diabetes, and metabolic syndrome globally. Enhanced awareness among healthcare providers and patients, coupled with advancements in diagnostic technologies such as non-invasive imaging and biomarkers, are facilitating early detection and effective management of the disease. The introduction of novel therapeutics, such as Rezdiffra (resmetirom) for NASH with moderate to severe liver scarring, is also contributing to market expansion. However, challenges like stringent regulatory requirements, high treatment costs, and lack of widespread awareness may hinder progress. 

Non-Alcoholic Fatty Liver Disease Drugs Uptake

This section focuses on the uptake rate of potential Non-Alcoholic Fatty Liver Disease drugs expected to be launched in the market during 2024–2034, which depends on the competitive landscape, safety, and efficacy data along with order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake. 

Non-Alcoholic Fatty Liver Disease Pipeline Development Activities

The Non-Alcoholic Fatty Liver Disease Therapeutics Market Report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key Non-Alcoholic Fatty Liver Disease Companies involved in developing targeted therapeutics. The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Non-Alcoholic Fatty Liver Disease emerging therapies. 

Latest KOL Views on Non-Alcoholic Fatty Liver Disease

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility. DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging treatment patterns of Non-Alcoholic Fatty Liver Disease. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Non-Alcoholic Fatty Liver Disease Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival. Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided. 

Non-Alcoholic Fatty Liver Disease Market Access and Reimbursement

The report provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Non-Alcoholic Fatty Liver Disease Market Report Scope

• The Non-Alcoholic Fatty Liver Disease treatment market report covers a segment of key events, an executive summary, descriptive overview, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along with country specific treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Non-Alcoholic Fatty Liver Disease Treatment Market, historical and forecasted Non-Alcoholic Fatty Liver Disease Market Size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Non-Alcoholic Fatty Liver Disease Treatment Market Report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Non-Alcoholic Fatty Liver Disease Drugs Market.

Non-Alcoholic Fatty Liver Disease Market Report Insights

• Patient-based Non-Alcoholic Fatty Liver Disease Market Forecasting
• Therapeutic Approaches
• Non-Alcoholic Fatty Liver Disease Pipeline Analysis
• Non-Alcoholic Fatty Liver Disease Market Size and Trends
• Existing and future Non-Alcoholic Fatty Liver Disease Drugs Market Opportunity 

Non-Alcoholic Fatty Liver Disease Market Report Key Strengths

• 11 Years Non-Alcoholic Fatty Liver Disease Market Forecast
• 7MM Coverage 
• Non-Alcoholic Fatty Liver Disease Epidemiology Segmentation
• Inclusion of Country specific treatment guidelines
• KOL’s feedback on approved and emerging therapies 
• Key Cross Competition 
• Conjoint analysis
• Non-Alcoholic Fatty Liver Disease Drugs Uptake
• Key Non-Alcoholic Fatty Liver Disease Market Forecast Assumptions

Non-Alcoholic Fatty Liver Disease Market Report Assessment

• Current Non-Alcoholic Fatty Liver Disease Treatment Practices
• Non-Alcoholic Fatty Liver Disease Unmet Needs
• Non-Alcoholic Fatty Liver Disease Pipeline Drugs Profiles
• Non-Alcoholic Fatty Liver Disease Drugs Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions Answered in the Non-Alcoholic Fatty Liver Disease Market Report

• What is the growth rate of the 7MM Non-Alcoholic Fatty Liver Disease treatment market?
• What was the Non-Alcoholic Fatty Liver Disease market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like in 2034? What are the contributing factors/key catalysts for this growth?
• Is there any unexplored patient setting that can open the window for growth in the future?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends? 
• What are the current and emerging options for the treatment of Non-Alcoholic Fatty Liver Disease? 
• How many companies are developing therapies for the treatment of Non-Alcoholic Fatty Liver Disease?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies? 
• Patient/physician acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? 

Reasons to Buy the Non-Alcoholic Fatty Liver Disease Market Report

• The Non-Alcoholic Fatty Liver Disease therapeutics market report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Non-Alcoholic Fatty Liver Disease Market.
• Insights on patient burden/disease Non-Alcoholic Fatty Liver Disease Prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the Non-Alcoholic Fatty Liver Disease Drugs Market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing Non-Alcoholic Fatty Liver Disease treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Non-Alcoholic Fatty Liver Disease Drugs Market so that the upcoming players can strengthen their development and launch strategy.

Stay updated with us for Recent Articles @ New DelveInsight Blogs